Eight patients experienced a loco-regional relapse: contralateral breast (n = 1 1.0%), ipsilateral breast (n = 4 4.1%), chest wall (n = 1 1.0%), axilla (n = 2 2.1%).
Sentinel node biopsy free#
The median follow-up was 35 months (range 1 to 148), and median disease free survival was 40.8 months. Positive SLN's were found in 22 patients (6 micrometastases and 2 isolated tumor cells, of which 4 patients did not undergo ALND), 18 subsequent ALND's were performed. Mean number of SLN's was 2.2 (range 0-7). Mapping was unsuccessful in one patient, who had subsequent axillary lymph node dissection (ALND). The SLN detection techniques were as follows: 99mTC albumin nanocolloid-only (n = 71 73.2%), blue dye-only (n = 1 1.0%), combined technique (n= 9 9.3%), and unknown (n = 16 16.5%). Median age at diagnosis was 35 years (range 28-45). Breast cancer diagnosis was made before pregnancy, in the first, second, and third trimester in 2, 34, 36 and 19 patients respectively (unknown n = 6). These results are comparable to the rates reported in the literature and shows that, in nonspecialized centers, this approach is safe and reproducible without affecting cancer-specific outcomes.Results: We identified a total of 97 women (INCIP n = 83 GBG n = 14). No recurrences occurred in this cohort with a median follow-up of 22 months.Ĭonclusions: SLNB is a sensitive and specific method for assessing lymph-node involvement in patients with clinical stage-I endometrial cancers. No other patients had false–negative SLNs. Non-SLNs were positive in 3 patients, all with high-risk histologies.
At least 1 SLN was detected in 95.4% of cases. The majority of cancers were endometrioid (73%), followed by UPSC (15.0%), MMMT (5.0%), and CC (4%). Results: A total of 92 cases were included: 69 stage IA 12 stage IB 3 stage II and 8 stage III (2 IIIA, 2 IIIC1, 4 IIIC2). The medical records were queried for clinical or radiographic evidence of recurrences.
Sentinel node biopsy serial#
Sentinel lymph nodes (SLNs) were evaluated using ultrastaging protocols with serial sectioning and cytokeratin staining. In addition to SLNB, PPALND was performed for patients with MMMT, UPSC, or CC. Para-aortic LND was performed at the discretion of the surgeon. Per the algorithm, patients with suboptimal lymph-node mapping or nodes suspicious for metastasis underwent a side-specific pelvic lymph-node dissection (LND). Indocyanine green was injected into the cervix bilaterally. All patients had undergone either robot-assisted or laparoscopic hysterectomies with SLNB. Endometrioid, uterine papillary serous (UPSC), malignant mixed-mesodermal tumor (MMMT), and clear-cell (CC) histologies were included. Materials and Methods: Cases of patients with clinical stage-I endometrial cancer were retrospectively reviewed from September 2016 through February 2020. The aim of this research was to demonstrate that SLNB is feasible, reproducible, and sensitive without affecting cancer-specific outcomes when implemented at nonspecialized centers. These data have been largely published from high-volume specialized institutions, but complete PPALND is still performed by many surgeons at smaller nonspecialized centers.
Objective: Sentinel lymph-node biopsy (SLNB) is now as alternative to pelvic and para-aortic lymph-node dissection (PPALND) for managing endometrial cancers.